Investing.com - TD Cowen 对 Akero Therapeutics (NASDAQ: AKRO) 启动覆盖，给予买入评级，目标价为 76.00 美元。根据 InvestingPro 数据，这与分析师的强烈共识一致，目标价范围在每股 60 美元至 109 美元之间。该公司股票表现出令人印象深刻的增长势头，过去一年回报率达 92%。

I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Investing.com - TD Cowen周一首次给予Akero Therapeutics (NASDAQ: AKRO )买入评级，目标价为76.00美元。该公司目前市值为39.1亿美元，其股票在过去一年中上涨了超过92%。 该研究机构强调了公司的FGF21类似物efruxifermin (EFX)，指出其差异化的临床特性得到了强有力的疗效数据支持，这可能推动其在F3和F4 ...

Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with ...

EFX的耐受性良好，最常见的不良事件是1级或2级胃肠道事件（腹泻、恶心和食欲增加）。 1例接受EFX治疗的患者因恶心而停药，1例在撤回同意后停药。

Efx Fragments is available now at an introductory price of $99, though if you already own other Arturia products there's probably a steep discount waiting for you.

Find the latest Equifax Inc. (EFX) stock quote, history, news and other vital information to help you with your stock trading and investing.